Background: The use of simplified methods for viral load determination could greatly increase access to treatment monitoring of HIV patients in resource-limited countries. Objective: The aim of the present study was to optimize and evaluate the performance of the Roche COBAS Taqman assay in HIV-RNA quantification from dried blood spots (DBS) and dried plasma spots (DPS). Study design: EDTA blood samples from 108 HIV-infected women were used to prepare 129 DBS and 76 DPS on Whatman 903 card. DBS and DPS were stored at −20
Background
Access to antiretroviral drugs in resource-limited countries has significantly increased in the last years and at the end of the year 2007 about 3 million people were receiving antiretroviral therapy (a 7.5-fold increase during the last four years). 1 Although this coverage is still low, representing only 31% of people requiring treatment, there is an urgent need to evaluate simplified methods to monitor treatment efficacy and to guide an appropriate switch to second line therapy. Evidence has been accumulating that identification of treatment failure based only on clinical or immunological criteria, can be unsatisfactory because of a late identification of virologic failure with consequent accumulation of resistance mutations. 2, 3 The use of dried blood spots and dried plasma spots for viral load determination has been proposed because of the easiness of collection and the possibility of transport at room temperature (also from rural areas) to a centralized laboratory with molecular biology facilities.
Quantification of HIV-RNA from filter papers has been evaluated in several studies using different techniques that have provided variable results. [4] [5] [6] [7] [8] [9] In general, satisfactory results have been obtained at relatively high viral load, while samples with values near the cut-off level have not produced reliable data. [10] [11] [12] Recently, new assays for HIV-RNA determination using the realtime PCR methodology have been introduced and the performance of these new viral load assays with dried blood spots has not been extensively reported.
Objectives
In the present study we evaluated the performance of the Roche COBAS TaqMan assay in quantifying HIV-RNA from both dried blood spots and dried plasma spots obtained from patients in Malawi.
Study design

Patients
From February 2008 to October 2008, blood samples were collected in EDTA from 108 HIV-infected pregnant women attending the Drug Resource Enhancement Against AIDS and Malnutrition (DREAM) program (designed and managed by the Community of S. Egidio) in Lilongwe and Blantyre (Malawi) and enrolled in a study to evaluate prevention of breastfeeding associated transmission by HAART administration [SMAC (Safe Milk for African Children) study]. The study was approved by the National Health Research Committee of Malawi.
Blood samples were collected in 102 women before initiation of antiretroviral therapy and in 18 women after 2-6 months of treatment (regimen included stavudine or zidovudine + lamivudine + either nevirapine or lopinavir/ritonavir). HIV-1 subtype C is highly prevalent in Malawi. 13 
Preparation of specimens
All procedures were performed by locally trained people under tropical climate conditions. For dried blood spots (DBS) 75 l of EDTA-collected blood samples were spotted onto each circle of Whatman 903 filter paper card. After centrifugation at 800-1000 × g for 15 min of the EDTA-collected blood, an aliquot of plasma was stored at −80 • C and 50 l were spotted on Whatman 903 cards to prepare dried plasma spots (DPS). Both DBS and DPS were dried at room temperature for 4 h and then stored in individual ziplock bags containing a desiccant at −20 • C until shipment to the laboratory of the Istituto Superiore di Sanità in Italy. DBS and DPS were shipped at room temperature and in Italy stored at −20 • C until processing. Plasma samples were shipped in dry ice and stored at −80 • C until processing.
Processing of specimens
Initially, HIV-RNA extraction from DBS and DPS was attempted using the High Pure System Viral Nucleic Acid kit (manual extraction of the Roche COBAS TaqMan assay) but a significant underestimation of results was obtained. Subsequently therefore, HIV-RNA extraction was performed with the NucliSENS miniMAG system (bioMerieux, Marcy l'Etoile, France) using the Boom technology with magnetic silica. Each spot was excised and incubated overnight at room temperature in 2 ml of NucliSENS lysis buffer with gentle rotation. The filter paper was then removed from the tube and the solution was processed according to the manufacturer's instructions; the nucleic acids obtained were then processed for quantification using the COBAS TaqMan real-time reverse transcriptase PCR assay (Roche Diagnostics, Branchburg, NJ, USA). All plasma samples were extracted with the High Pure Viral Nucleic Acid kit and quantified with the Roche TaqMan assay with a limit of detection of 47 copies/ml (1.67 log 10 copies/ml) (on the basis of a plasma input volume of 500 l). When the sample volumes were reduced to 75 l for DBS and 50 l for DPS, the limits of detection were 313 copies (2.49 log 10 copies/ml) and 470 copies (2.67 log 10 copies/ml) respectively.
Data analysis
All HIV-RNA values were log 10 transformed before analysis. Quantitative variables are expressed as means (±SD) and compared by the Student t-test. Log-transformed viral load measured in DBS and DPS samples and in the paired liquid plasma samples were compared by Pearson correlation analysis. For the analysis of concordance between the results obtained from plasma and those obtained from DBS and DPS, the method of Bland and Altman was used. 14 All statistical calculations were performed using SPSS software (version 17.0, SPSS Inc. Chicago, USA).
Results
Samples were divided according to the HIV-RNA level in plasma: ≤2 log 10 (n = 19, all obtained from treated women), 2 log 10 (range 2.1-2.96, n = 15), 3 log 10 (range 3.04-3.97, n = 28), 4 log 10 (range 4.0-4.97 n = 38), 5 log 10 (range 5.01-6.01, n = 29). DBS were available for all collected plasma samples (n 129) while 76 DPS were available for the analyses. Samples were analyzed after a mean time of 10.4 months (range 2-17.2 months) of collection and storage. Fig. 1 shows the correlation between the viral load determinations from plasma and from DBS. The overall R 2 was 0.939. Agreement between undetectable and detectable viral load for plasma and DBS was seen in 89.1% of samples. In 10% of the cases (n 13) HIV-RNA was not detectable in DBS while measurable levels were present in plasma (between 2.1 and 3.04 logs, mean 2.49). One DBS gave a result of 2.74 log 10 (549 copies) while the corresponding plasma level was <1.67 log copies. In all other cases of undetectable viral load in plasma (n 18) HIV-RNA was not detectable in DBS.
The correlation between levels measured in DPS and in plasma is shown in Fig. 2 . Agreement between undetectable and detectable viral load was seen for 92.1% of the samples. There were 7 samples with undetectable HIV-RNA in plasma and all of them were undetectable when measured from DPS. In 7.9% of the cases (n 6) HIV-RNA was undetectable in DPS while measurable HIV-RNA levels were present in plasma (between 2.1. and 3.3 logs, mean 2.50). Detection rates according to different HIV-RNA thresholds for DBS and DPS are reported in Table 1 . Both DBS and DPS had a high sensitivity and specificity and a high Positive Predictive Value (Table 2) . Negative Predictive Values were low as an effect of the low rate of detection of both DBS and DPS when plasma HIV-RNA was below 3.0 log copies/ml. Among samples with detectable HIV-RNA, the correlation between viral load values obtained from the paired 97 plasma and DBS samples and the 63 plasma and DPS samples was high (Pearson correlation coefficient = 0.96, and 0.85, R 2 = 0.92 and 0.72, respectively, P < 0.01 for both correlations). The mean (±SD) difference between the measured viral load in DBS samples and in plasma was 0.32 ± 0.22 log copies/ml. The mean difference for DPS was 0.35 ± 0.33 log copies/ml. HIV-RNA levels obtained from DBS were always lower than in plasma with the exception of 9 out of 97 samples (9.3%) in which levels were higher (from 0.02 to 0.43 log higher, plasma HIV-RNA range 2.75-4.08 logs). In 7 out of 63 cases (11.1%) DPS had HIV-RNA levels higher than in plasma (from 0.01 to 0.39 logs higher than in plasma, HIV-RNA range 2.96-4.35 logs). The mean (±SD) HIV-RNA levels (log 10 ) in plasma and DBS were 4.45 ± 0.79 and 4.13 ± 0.71, respectively (P < 0.001). The corresponding values comparing plasma and DPS were 4.17 ± 0.63 and 3.82 ± 0.53, respectively (P < 0.001).
Overall, viral load values between DBS and plasma differed by less than 0.5 log unit in 78.4% of the samples and by less than 1 log unit in 100% of the samples. For DPS the corresponding figures were 73% (less than 0.5 log) and 96.8% (less than 1 log).
Agreement between the two samples was calculated by the Bland and Altman method, in which the differences between individual viral load results from plasma and spots are plotted against the mean of the two results (concordance is good when the differences are within the limits of 1.96 standard deviations of the mean). In Figs. 3 and 4 it can be seen that all but 1 sample were within the 1.96 SD limits (−0.30-0.94) for DBS and all but 4 samples were within the limits (−0.36-1.07) for DPS, respectively. 
Discussion
Assessing the reliability of dried blood spots or dried plasma spots for the detection of virological failure is a high priority research question for resource-limited settings. The performance in HIV-RNA quantification from DBS and DPS of the new methodologies for viral load determination using a real-time PCR have been evaluated in few studies, 9, 10, 12, 15 and in our work we aimed to validate the use of the Roche COBAS TaqMan assay. To obtain good results we had to adapt the methodology and perform the extraction with the Boom technology since in our hands (and as reported by others 11 ) the High Pure Viral Nucleic Acid kit (manual extraction of the Roche COBAS TaqMan assay) was not efficient due to a significant underestimation (mean difference >1.2 log compared to plasma, data not shown). Following this modification we found a very good agreement between the results in plasma and in both DBS and DPS. The rate of detection at the viral threshold commonly defining virologic failure was >95% and both DBS and DPS had a very high Positive Predictive Value. Although we did not adjust for hematocrit our data from DBS, we found very similar results between DBS and DPS without any significant difference in detection rates or sensitivity. As hypothesized by others, 15, 16 it is possible that the difference due to hematocrit is compensated by the concentration of HIV-RNA present in the cells in whole blood. Since DBS eliminate the need for an initial centrifugation to separate plasma, the use of DBS is highly preferable especially for regions without electricity. Another very important aspect of our study is the stability of the results over time if DBS/DPS are stored at −20 • C (even if shipped from one laboratory to another at room temperature). In fact, our samples were processed after several months of collection and no correlation was found between the length of storage and the proportion of samples with >0.5 log difference between DBS and plasma (data not shown), although we cannot exclude that we could have obtained better results with a shorter storage. Indeed, a different study 12 assessing the performance of a real-time PCR assay, obtained greater sensitivity and a lower mean difference between plasma and DBS compared to our results, but it has to be underlined that we used a manual extraction method while in the paper by Marconi et al. an automated extraction was performed. However, the proportions of samples with >0.5 log or >1 log difference were similar in both studies.
In our work, unlike other reports, [10] [11] [12] we did not find false positive results with DBS. Only one sample that was undetectable in plasma had 549 copies/ml detected by DBS while the great majority of HIV-RNA levels obtained from DBS and DPS were lower than those obtained from plasma. The presence of proviral DNA in DBS was thought to be responsible for the presence of a large number of false positives with DBS. However, in our study the same (very limited) proportion of samples among DBS and DPS had values slightly higher than plasma (in the range of the variability of the method). Therefore, it seems that alternative hypotheses should also be considered for the results of the above mentioned studies.
In conclusion, in our study DBS and DPS, easily transported at room temperature from distant sites to reference laboratories (where storage at −20 • C is generally possible), are highly sensitive in detecting virological failure and can contribute to increase access to virological monitoring of patients in resource-limited settings.
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